1-2 of 2
Mattias Rantalainen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost, Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, Willem Lybaert, Els G. Everaert, Daan De Maeseneer, Michiel Strijbos, Alain Bols, Karen Fransis, Nick Beije, Inge E. de Kruijff, Valerie van Dam, Anja Brouwer, Dirk Goossens, Lien Heyrman, Gert G. Van den Eynden, Annemie Rutten, Jurgen Del Favero, Mattias Rantalainen, Prabhakar Rajan, Stefan Sleijfer, Anders Ullén, Jeffrey Yachnin, Henrik Grönberg, Steven J. Van Laere, Johan Lindberg, Luc Y. Dirix
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (6): 1766–1773.
https://doi.org/10.1158/1078-0432.CCR-18-1943
Published: 15 March 2019
View article titled, <em>TP53</em> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for <em>TP53</em> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes

Jingmei Li, Emma Ivansson, Daniel Klevebring, Nicholas P. Tobin, Linda Sofie Lindström, Johanna Holm, Gabriela Prochazka, Camilla Cristando, Juni Palmgren, Sven Törnberg, Keith Humphreys, Johan Hartman, Jan Frisell, Mattias Rantalainen, Johan Lindberg, Per Hall, Jonas Bergh, Henrik Grönberg, Kamila Czene
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2584–2592.
https://doi.org/10.1158/1078-0432.CCR-16-0967
Published: 14 May 2017
View article titled, Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes
Open the PDF for Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes in another window
Includes: Supplementary data